Development, validation, and evaluation of the PBC-40, a disease specific health related quality of life measure for primary biliary cirrhosis.
about
Primary biliary cirrhosis: Pathophysiology, clinical presentation and therapyAssociation between cytotoxic T-lymphocyte antigen 4 gene polymorphisms and primary biliary cirrhosis in Chinese population: data from a multicenter study.Promoting self-management and adherence with strength and balance training for older people with long-term conditions: a mixed-methods study.Translation and validation of the Serbian primary biliary cholangitis-40 questionnaireVariant adiponutrin confers genetic protection against cholestatic itchQuality of life and everyday activities in patients with primary biliary cirrhosis.The impact of fragility fractures on health-related quality of life in patients with primary sclerosing cholangitis.Four year follow up of fatigue in a geographically defined primary biliary cirrhosis patient cohortExpression of hepatic Fibroblast Growth Factor 19 is enhanced in Primary Biliary Cirrhosis and correlates with severity of the diseaseRITPBC: B-cell depleting therapy (rituximab) as a treatment for fatigue in primary biliary cirrhosis: study protocol for a randomised controlled trialBAT117213: Ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis: study protocol for a randomised controlled trialThe impact of osteoporosis on health-related quality of life in patients after liver transplantation - a pilot studyTRAF1-C5 affects quality of life in patients with primary biliary cirrhosisSerum Autotaxin is a Marker of the Severity of Liver Injury and Overall Survival in Patients with Cholestatic Liver Diseases.Early primary biliary cholangitis is characterised by brain abnormalities on cerebral magnetic resonance imaging.The inter-relationship of symptom severity and quality of life in 2055 patients with primary biliary cholangitis.A systematic approach to the management of cholestatic pruritus in primary biliary cirrhosis.Primary Biliary Cholangitis Alters Functional Connections of the Brain's Deep Gray Matter.Thyroid Dysfunction in Primary Biliary Cholangitis: A Comparative Study at Two European Centers.Therapeutic Equivalence of Ursodeoxycholic Acid Tablets and Ursodeoxycholic Acid Capsules for the Treatment of Primary Biliary Cirrhosis.Factors that Influence Health-Related Quality of Life in Patients with Primary Sclerosing Cholangitis.Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: A proof-of-concept study.Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid.The specificity of fatigue in primary biliary cirrhosis: evaluation of a large clinic practice.Impact of primary biliary cirrhosis on perceived quality of life: the UK-PBC national study.Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis.The impact of biopsychosocial factors on quality of life: women with primary biliary cirrhosis on waiting list and post liver transplantation.Patients with primary biliary cholangitis and fatigue present with depressive symptoms and selected cognitive deficits, but with normal attention performance and brain structure.A disease-specific quality of life instrument for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: CLDQ-NAFLD.Prospective evaluation of PBC-specific health-related quality of life questionnaires in patients with primary sclerosing cholangitis.The role of psychological factors in the fatigue of primary biliary cirrhosis.The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines.Obeticholic Acid: A Farnesoid X Receptor Agonist for Primary Biliary Cholangitis.Pilot study with IBAT inhibitor A4250 for the treatment of cholestatic pruritus in primary biliary cholangitis.A real-world observational cohort of patients with primary biliary cholangitis: TARGET-primary biliary cholangitis study design and rationale.Magnetic resonance imaging evidence of hippocampal structural changes in patients with primary biliary cholangitis.NGM282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled TrialSymptoms and health-related quality of life in Japanese patients with primary biliary cholangitisMorning Bright Light Treatment for Sleep-Wake Disturbances in Primary Biliary Cholangitis: A Pilot Study
P2860
Q26853649-5E64D17C-A931-4CA5-87A4-303D201CC3D1Q30592653-0B07DEB3-9719-4BBA-B767-F9EA38CC38C4Q33164185-A204940E-6A1D-4DA3-BF95-A1F904F396F5Q33563053-C596F3DF-029F-4015-A643-D6B9A3161E7CQ34309870-67D32903-F1A8-4DD1-86C7-71F0A6211D47Q35142961-96BF4D62-EFE4-43F9-9A34-D31C08774E8FQ35589931-F237DC2B-2B8A-4A9F-B8BE-4BA69BC6DE6FQ35760389-26D0557C-9C53-4082-83F5-C889302D236FQ35979451-045C550A-E8FA-4C18-9332-52D398C7BB18Q35998928-262CDE85-A3FA-4E23-915C-9477900F0E98Q36080972-F563689A-2B16-4C36-A016-8471A681A584Q36418947-33B21353-BE8A-41C5-AC27-955A72D5EDFAQ36848255-93A8B02F-F284-457C-AE40-E1C6AECF6AE7Q37163154-7DD2E90D-F257-464B-9821-9BB9A99727F8Q37371069-77CA08DC-5158-4732-9F83-3AF1A04563B7Q37371109-D169ADF9-745A-4AD3-813E-E985CC6F5227Q38637490-FE442900-12A4-473D-8CE8-D8FF7779A089Q38651060-318E42CC-5F5F-45B6-9EF2-7C9D45296AA6Q39251599-18CBC46B-42C3-4B0C-BA1F-4F7A0908898FQ39816216-9F296AD7-3737-4A60-ADE7-EC06E05880F3Q40130719-FD55EA41-8269-4D64-ABDB-0DC14D418776Q40898741-417A9944-0265-431F-B519-98BBC99619FAQ42620850-6ECB5E12-8707-497F-A987-4E1A9F692AF1Q43589988-4C4FFCCD-4AE7-464C-BB41-FEA8B84501D0Q43725734-98CCF255-AD09-4A75-BEDD-2C89D7E7E71EQ46933007-7C9956C8-B9A3-4635-9EB2-B8FCB9663228Q47285348-AAC8BFE0-481D-4A8E-8778-33E0EC41E35CQ47555624-A8ED7E45-A1FC-4349-9EDF-807B542ECD25Q47966842-29E80FCB-68B5-4497-B111-321A056C8168Q48060155-01074E2F-B5D5-4A72-8D80-323525202999Q50900931-B1E4882A-D312-4511-9E2E-99CDAC8CAF45Q52624982-7EE68172-78F2-4793-8F1F-E78090B6E47BQ55165714-9478A718-606B-4122-9506-B8037C612D16Q55192048-9C62BA2C-68E1-4CA0-9FF3-5F79A11FEB91Q55379081-30387186-30B1-4115-9C8B-E65096DB71E4Q55498617-09048147-B98F-409C-8060-6290D70A4497Q57110523-3997FF30-4397-4C39-A3A2-54DEC51364E6Q58722495-00355683-F7C0-499A-8745-93D342F0F715Q59136991-A4769055-4DB5-4CC2-A3A0-768143E47146
P2860
Development, validation, and evaluation of the PBC-40, a disease specific health related quality of life measure for primary biliary cirrhosis.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Development, validation, and e ...... for primary biliary cirrhosis.
@ast
Development, validation, and e ...... for primary biliary cirrhosis.
@en
Development, validation, and e ...... for primary biliary cirrhosis.
@nl
type
label
Development, validation, and e ...... for primary biliary cirrhosis.
@ast
Development, validation, and e ...... for primary biliary cirrhosis.
@en
Development, validation, and e ...... for primary biliary cirrhosis.
@nl
prefLabel
Development, validation, and e ...... for primary biliary cirrhosis.
@ast
Development, validation, and e ...... for primary biliary cirrhosis.
@en
Development, validation, and e ...... for primary biliary cirrhosis.
@nl
P2093
P2860
P356
P1433
P1476
Development, validation, and e ...... for primary biliary cirrhosis.
@en
P2093
P2860
P304
P356
10.1136/GUT.2005.065862
P407
P50
P577
2005-06-16T00:00:00Z